Icon
+91 94997 68112
Login Register

EXTINA (nda021738)- (2%)

KETOCONAZOLE MYLAN
2%
Yes Yes
2018-Oct-19 Expired
None None
None No
EXTINA® Foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
2 0 2
Total Other Developers 1
Drugs with Suitability No
2% ** ** - - 2
NDA Sales Available Total Generic Sales Available
Yes 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ****** ******* ****** *************** *** *********** * ********* ***, *******, *******, ****** (***) ***
****** ******* ************ ******* *** *********** ******** ********** ********** *, ******** ** *******, *****, ***** (***) ***
****** ******* ************ ******* *** *********** ******* ** ********** *, ****** ** *******, ******** ** ******* *****, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.